Cellinfinity Bio

Cellinfinity Bio is developing next-generation, 'Supercharged In Vivo Cell Therapies' designed to reprogram a patient's own immune cells inside the body, bypassing the costly and complex ex vivo manufacturing of traditional autologous CAR-T. The company's platform applies directed evolution across four key areas—scFv discovery, vector engineering, CAR design, and genomic enhancements—to create therapies that can overcome the immunosuppressive barriers of solid tumors. With a preclinical pipeline targeting solid tumors, Cellinfinity aims to simplify cell therapy delivery and expand its efficacy beyond hematological cancers into areas of high unmet need.

A proprietary platform applying directed evolution across four pillars: scFv Evolution for novel target discovery, Vector Evolution for in vivo delivery, CAR Evolution for architecture optimization, and Genomic Evolution for incorporating enhancements to overcome the solid tumor microenvironment.

Cellinfinity competes in the rapidly evolving field of next-generation CAR-T therapies, facing numerous biotechs developing armored CARs, allogeneic (off-the-shelf) approaches, and novel solid tumor targets. Its direct competition includes companies like Umoja Biopharma, Ensoma, and other in vivo engineering startups, as well as large pharma with internal cell therapy divisions.